Premium
Morphine in primary percutaneous coronary intervention—No pain, questionable gain
Author(s) -
Sridharan Aadhavi,
Kimmelstiel Carey
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29091
Subject(s) - medicine , percutaneous coronary intervention , conventional pci , morphine , myocardial infarction , p2y12 , cardiology , anesthesia , ticagrelor , clinical trial
Key Points The clinical impact of concurrently administered morphine and P2Y12 inhibitors in primary percutaneous coronary intervention (PCI) is not well understood. Large, randomized clinical trials are required to assess clinical outcomes with concurrent morphine and P2Y12 inhibitor use in ST‐segment elevation myocardial infarction patients undergoing PCI. Based on the currently available pharmacologic data, cautious use of morphine in primary PCI would seem prudent.